Overview
Dr. Megan Clowse is a Professor of Medicine and Chief of the Division of Rheumatology and Immunology; she also holds joint appointments in the Department of Obstetrics and Gynecology and Population Health Sciences. Her clinical research focuses on the management of rheumatic diseases in pregnancy. She has cared for over 1000 pregnancies in women with rheumatic disease, collecting information on these pregnancies initially in the Duke Autoimmunity in Pregnancy Registry and Repository, and the MADRA (Maternal Autoimmune Disease Research Alliance) registry and repository. She served on the Core Leadership Team for the inaugural American College of Rheumatology's Reproductive Health Guidelines, published January 2020. Dr. Clowse created www.LupusPregnancy.org and www.ReproRheum.Duke.edu, websites dedicated to improving pregnancy planning and management for patients and rheumatologists.
Dr. Clowse was the founding director of the Duke Lupus Clinic, where she continues to see patients each week and mentor junior faculty researchers. The team has developed a new approach to lupus classification and management and is currently collecting and analyzing patient- and physician-reported measures to better clarify this construct.
Current Duke Appointments & Affiliations
Recent News Items
View All News Items
Recent Scholarly Works
The relationship between autoantibody and complement levels in the sera of patients with systemic lupus erythematosus.
Journal article Clin Immunol · September 25, 2026 The goal of these studies was to elucidate the relationship between levels of autoantibodies and complement (C3/C4) in the sera of patients with systemic lupus erythematosus (SLE) and thereby provide a framework for interpreting serological biomarkers in t ... Full text Link to item CiteThe Plot Thickens: From a Classic Presentation to Bilateral Renal Lesions.
Journal article Arthritis Care Res (Hoboken) · September 2026 Full text Link to item CiteA quality improvement project to incorporate the mycophenolate Risk Evaluation and Mitigation Strategies in an academic lupus clinic
Conference Lupus · August 1, 2026 Background/Purpose: Mycophenolate compound (MMF, to represent both mycophenolate mofetil and mycophenolic acid) is an immunosuppressant used to treat Systemic Lupus Erythematosus (SLE). Due to its teratogenicity, the FDA recommends universal mycophenolate ... Full text CiteRecent Grants
A multicenter, open-label, prospective study to assess the concentration of Bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma · 2025 - 2031Azathioprine Safety and Pharmacokinetics in Pregnant Women with Rheumatic Disease and their Infants
ResearchCo Investigator · Awarded by National Institutes of Health · 2026 - 20312/3 CTSA K12 Program at Duke University
ResearchMentor · Awarded by National Center for Advancing Translational Sciences · 2025 - 2030View All Grants